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Background: Information about the possible effect of rheumatic diseases on male sexual function and repro-
duction (sexual health) is scarce and difﬁcult to summarize. Factors known to impair sexual health, such as
inﬂammation, medication use and hypogonadism can be present in a signiﬁcant proportion of male patients
with rheumatic diseases.
Objectives: The objective of our study was to systematically review the literature for the inﬂuence of paternal
rheumatic disease on sexual health, such as sexual function, reproductive hormones, male fertility, preg-
nancy and offspring outcomes.
Data sources: English language articles identiﬁed through Embase, MEDLINE, Cochrane Central Register of
Controlled Trials (CENTRAL), Web of Science, Google Scholar and the Clinical trial registries of Europe and
the USA published until February 2019.
Study appraisal and synthesis methods: Literature was synthesized in narrative form and in summary tables.
Outcomes were categorized as: sexual function, reproductive hormones, fertility and pregnancy and off-
spring outcomes. Results are presented per category and per disease.
Results: 9735 articles were identiﬁed with our search strategy. After removal of duplicates, excluding articles by
screening titles and abstracts and assessing eligibility by reading 289 fulltext articles, 87 articles fulﬁlled the eli-
gibility criteria. All included studies enrolled patients diagnosed with a rheumatic disease and had results at
least on one of the outcome categories. Sexual function was the most common category, followed by reproduc-
tive hormones, fertility and pregnancy and offspring outcomes. Sexual function is impaired in a high proportion
of patients with rheumatic diseases. This was statistically signiﬁcant in most of the studies where a control
group was available. Clinically relevant abnormalities in reproductive hormones were mainly identiﬁed in
patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and a positive correlation
with disease activity were reported. Semen quality in men with rheumatic diseases can be impaired in patients
with SLE, SpA, sarcoidosis, BD and MWS. Sperm count and motility were the most common semen quality
parameters affected. No negative effect of paternal RA and vasculitis on pregnancy outcomes were reported in
3 studies. No studies reporting the effect of paternal disease on offspring outcomes were identiﬁed.
Limitations: Most of the studies included in this review suffer from an inconsistent methodological quality,
deﬁnitions of outcomes varied in several studies, a wide variety of screening questionnaires and/or diagnos-
tic tools were used and results might only apply to the speciﬁc populations that were studied.
Conclusions: This systematic review suggests that sexual health is impaired in men with rheumatic diseases.
The degree and extent of sexual health impairment vary per disease. More research is needed to fullyKeywords:
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gists should be aware of this association and discuss it with their patients.
Implications of key ﬁndings: Sexual health of men with rheumatic diseases can be impaired by the disease
itself. Especially in men trying to conceive, information on sexual function, reproductive hormones and
sperm quality are needed to identify these problems. Treatment resulting in lower disease activity can
improve overall sexual health in man with rheumatic diseases and facilitate their journey to fatherhood.
Systematic review registration number: PROSPERO 2018 CRD42018099845.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Clinical case
A 38-year-old man was recently diagnosed with rheumatoid
arthritis (RA). During the ﬁrst follow up appointment he informs his
rheumatologist, that he and his wife wish to conceive in the near
future. For this reason, they want information about whether RA can
affect sexuality and pregnancy outcomes. During the discussion it
becomes apparent that the patient is having problems regarding his
sexual function; sexual intercourse causes pain and sometimes get-
ting an erection is difﬁcult. He is worried that his RA could interfere
with his sexual health and more importantly, his desire to become a
father. The rheumatologist discusses treatment strategies that are
known to be safe in men with a wish to conceive and promises to
come back to him with more information about RA related sexual
health outcomes. Thereafter, the rheumatologist discusses with some
of his colleagues several questions:
1. Can rheumatic diseases affect male sexual function, reproductive
hormones, fertility and pregnancy outcomes? Can disease activ-
ity impair male sexual health?
2. Which sexual health problems are common in male patients with
rheumatic diseases?
3. In male patients with rheumatic disease, what is the importance
of good paternal health for positive pregnancy and offspring out-
comes?
Introduction
Rationale
This case described above represents a frequent clinical scenario
for rheumatologists around the world. For many years rheumatic dis-
eases have been considered as diseases of women though it is esti-
mated that the overall lifetime risk for developing a rheumatic
disease for men is 1 in 20 [1]. Especially in studies on reproductive
rheumatology, there is a clear gender bias that has resulted in signiﬁ-
cant scientiﬁc knowledge focused only on the female perspective.
Reducing this knowledge gap is important because sexual health and
reproduction are as important for men as it is for women.
Sexual health, the state of physical, mental and social well-being
in relation to sexuality, has been recognized as an important factor
than can have positive or negative effects in an individual’s quality of
life and the World Health Organization (WHO) states that sexual
health problems require speciﬁc action for their identiﬁcation, pre-
vention and treatment. Men diagnosed with rheumatic diseases have
speciﬁc needs and thus require a health strategy of their own [2,3].
Nonetheless, information regarding this topic is scarce and scattered.
In addition to this, the WHO also considers the need to make
informed and responsible choices about reproduction as one of their
main sexual health concerns [4]. Human reproduction is a biological
process that requires the correct structure and function of several
organs and systems in men and women. For men, an adequate testic-
ular function that results in healthy spermatozoa can be considered
as one of the most important steps in male reproduction, but manyother factors contribute to the success of a spermatozoon fertilizing
an ovum, from a delicate balance among hormones secreted in the
hypophysis and the testicles (reproductive hormones) to spermato-
genesis and proper conditions for storage of the mature spermatozoa
(fertility) to intercourse and ejaculation (sexual function).
All of these organs and physiologic processes can be impaired by
inﬂammation secondary to rheumatic diseases and could have detri-
mental effects on both reproductive function and pregnancy out-
comes [57]. In addition, other well-known factors have detrimental
effects on sexual health like chronic pain and fatigue, as well as psy-
chological factors, such as depression and anxiety, all of them highly
prevalent in patients with rheumatic diseases. Rheumatologists tak-
ing care of men with rheumatic diseases must consider this to adjust
treatment accordingly. Improving men's preconception health might
result in improved pregnancy outcomes by enhancing men's biologic
and genetic contributions to the pregnancy conception (pregnancy
and offspring outcomes) [8].
Information regarding the effect of rheumatic diseases on male
sexual health is needed to improve the way rheumatologists counsel
and treat male patients with rheumatic diseases.
Objective
The objective of our study was to systematically review the litera-
ture for the inﬂuence of paternal rheumatic disease on sexual health,
such as sexual function, reproductive hormones, male fertility, preg-
nancy outcome and on their offspring health outcome. This system-
atic review (SR) will answer the following questions:
 What is the inﬂuence of rheumatic diseases on male sexual
function?
 What is the inﬂuence of rheumatic diseases onmale fertility and
reproductive hormones?
 What is the inﬂuence of paternal rheumatic diseases on preg-
nancy and offspring outcomes?
Methods
Protocol and registration
This SR is part of a larger SR that included other immune-mediated
diseases (IMD) from Gastroenterology and Dermatology. The complete
protocol was registered in PROSPERO and is available in https://www.
crd.york.ac.uk/prospero/display_record.php?RecordID=99845. The pro-
tocol and this SR were written according to the PRISMA-P statement
[9,10].
Search
A search strategy was developed by an experienced medical
librarian (WMB) using a structured methodology [9,10]. The searches
combined keywords regarding male sexual function and fertility,
pregnancy outcomes and offspring’s health with a list of IMDs (which
included Rheumatic diseases). Our full electronic search strategy is
provided in supplement 1.
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A systematic literature search was performed in the bibliographic
databases: Embase (via Elsevier embase.com), MEDLINE via Ovid,
Cochrane Central Register of Trials (CENTRAL) and Web of Science
Core Collection. Additionally, Google Scholar and the Clinical trial
registries of Europe and the USA were searched. We also contacted
authors for further information and included references from the pri-
mary search publications, in case these were missed in our search.
The databases were searched from inception until February 2019.
Eligibility criteria
The literature search was limited to the English language and human
subjects. Case-control studies, cohort studies, cross-sectional studies,
case reports and case series were included. Conference abstracts from
before April 2016 were excluded if more recent conference abstracts
were found we contacted the authors and searched for published data.
Publications without original data, such as reviews, were excluded.
In the case of studies reporting pregnancy and offspring out-
comes, publications were included if the diagnosis of the IMD took
place before conception. In case of studies just reporting fertility
parameters (i.e. semen analysis, sexual dysfunction) we included
publications were the diagnosis of a rheumatic disease was taken
into consideration. No restrictions were made in regard to the com-
parison groups. The outcome data should include at least one of the
following outcomes; sexual function, reproductive hormones, fertil-
ity, pregnancy or offspring outcomes.
Study selection
All articles were imported into EndNote X9. After removal of dupli-
cates with the method described by Bramer [11], two reviewers (LP and
JC) independently and blindly screened titles, abstracts and full-text of
the records for eligibility. Disagreements were resolved by consensus
with the help of a third reviewer; RD, for sexual function, reproductive
hormones and fertility outcomes and BW for pregnancy outcomes.
Data collection process
Two reviewers (LP and JC) extracted relevant information for each
studied outcome from the included articles.
Risk of bias in individual studies
The methodological quality of the studies was assessed with the
Newcastle Ottawa Scale (NOS), developed for case-control and cohort
studies [12]. Case series were graded conform the cohort studies (with-
out controls). In the case of cross-sectional studies, an adapted scale was
used [13]. Using this method, points were awarded to each publication,
related to the selection of the study group, the comparability of the
study groups and the ascertainment of the outcomes. The score ranges
from 0 to 9, with scores >5 representing good-quality studies. The
results are presented in Tables 25. Quality assessment was done by LP
and JC for the sexual function, reproductive hormones and fertility data,
and the pregnancy and child outcome data by BW.
Synthesis of results
Sexual health outcomes were classiﬁed in 4 categories:
1. Sexual function (sexual dysfunction, premature ejaculation,
erectile dysfunction).
2. Reproductive hormones (testosterone, LH, FHS, inhibin).
3. Fertility (sperm quality, testicular volume, time to pregnancy,
number of children).4. Pregnancy and offspring outcomes (congenital malformations,
premature birth, impact on offspring).Additional analysis
Due to the diversity of the methods used to report outcomes of
interest in this SR performing a meta-analysis was not possible.
Results
Study selection
A total of 9735 references were identiﬁed (4505 from Embase,
3524 from Medline-Ovid, 1666 from Web of Science and 40 from
Cochrane central) and imported into EndNote X9. After removing
2851 duplicates, 6884 articles were eligible for title and abstract
screening. 6597 articles were excluded during this phase and 287
articles were eligible for full-text reading. 202 articles were excluded
after full-text reading (see ﬂowchart in Fig. 1) and 87 articles fulﬁlled
the criteria for rheumatic diseases.
Summary of ﬁndings per disease
Results are presented per disease and divided into 4 categories
(sexual function, reproductive hormones, fertility outcomes and preg-
nancy and offspring outcomes) (See Table 1).
Rheumatoid arthritis
Sexual function
Sexual function in RA was studied in 8 articles that included 282
patients with a mean age of 41.07 years. Three studies were in Euro-
pean populations, 3 in Africa, 1 in North America and 1 in Asia. Three
articles assessed Sexual Dysfunction (SD) by interview, the Interna-
tional Index of Erectile Function (IIEF) was used in 3 articles, the
Questionnaire for Screening Sexual Dysfunctions (QSD) in 1 article,
and ICD-9 diagnosis code in 1 article.
The prevalence of SD was signiﬁcantly higher in men with RA than
in healthy controls in all the included studies (range, 3362% vs
1140%, respectively), this was associated with disease activity and
other disease-related factors, such as fatigue and pain.
Elst et al. reported that 32 male patients with RA (mean age
46.2 § 7 years) and a diminished functional capacity had lesser sex-
ual motivation and that 9 (27%) of patients wanted advice from
experts for their sexual problems [14]. SD was common in 32 RA
patients (mean age 55 years), particularly impotence (deﬁned as the
inability to obtain an erection ﬁrm enough for vaginal penetration, or
the inability to sustain the erection until completion of intercourse)
was signiﬁcantly more prevalent in RA patients than in age-matched
controls (62% vs 40%, p<0.05).[15]
SD was reported in 49 out of 91 (53.8%) RA male patients (mean
age 51.4 § 9.4 years) in an Egyptian multicenter study. Using the IIEF,
a statistically signiﬁcant correlation between SD and several factors
that are usually present in RA patients was reported. These factors
were; pain, cardiovascular disease, age, disease activity, fatigue, ten-
der joint count and psychological status. Interestingly, the number of
intramuscular steroid injections, but not the oral intake of predni-
sone, was correlated with more SD [16].
Using the IIEF questionnaire in a case-control study, Gaber et al.
assessed the prevalence of SD in 29 RA male patients (mean age
45.2 § 12.1 years). A mean DAS28 score of 3.5 (standard deviation 1.45),
suggestive of moderate disease activity was reported. Overall, SD was
reported in 14 (48.3%) of patients vs 12 (33.3%) in controls (p = 0.2). All
SD parameters were signiﬁcantly higher in RA patients compared to con-
trols and multivariate regression analysis revealed that severe RA (DAS28
>5.1) was associated with a higher risk of SD (OR 2.7, 95% CI 1.09-6.05)
[17].
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included 76 male patients with RA (mean age 57.6 [standard deviation
10.6] years, mean DAS28 3.5 [standard deviation 1.45]) and found that
RA patients differed signiﬁcantly from 54 controls (mean age 54.9
[standard deviation 9.4]) regarding the frequency of sexual activities
and libido (lower in RA than in controls, p<0.05). Physical functioning
(p<0.01) and, to a lesser extent, disease duration and activity (p<0.05)
signiﬁcantly correlated with various sexual problems. Patients and
controls did not differ regarding sexual satisfaction [18]. In a compara-
ble study, Gordon et al. reported that among 31 RA patients (mean age
37 years), 10 (33%) admitted periods of erectile dysfunction (ED) and
that 15 (50%) experienced decreased libido [19].
In a study comparing 24 male young RA patients (mean age
31.3 § 7.35 years) and 18 age-matched healthy controls, Nasr et al.
reported that SD was present in 11 (45.8%) of these patients com-
pared to 2 (11.1%) controls. There were a signiﬁcant correlation
between dehydro-epiandrosterone sulfate (DHEA) levels, total and
free testosterone levels and the IIEF score (p = <0.001) [20].
In a large population-based study from Taiwan that analyzed the
data of 6319 patients diagnosed with ED, an association between ED
and prior diagnosis of RA was reported. The OR for prior RA diagnosis
among cases with ED was 1.67 (95%, CI 1.362.05) that of controls
after adjusting for several confounders [21].
Reproductive hormones
Results on reproductive hormones were reported in 3 RA-related
studies. In all of these studies, patients with RA were found to have
lower total and free testosterone levels than healthy controls.
The androgenic status of 31 male patients with RA (median age 55
years) was investigated by Gordon et al., after correcting for age-
related changes to the pituitary-testicular axis, patients with RA still
showed signiﬁcantly lower serum testosterone and signiﬁcantly
greater serum LH and FSH compared to 33 males with Ankylosing
Spondylitis (AS) (median age 37 years) and 95 age-matched healthy
controls. Serum FSH was signiﬁcantly higher in RA patients compared
to healthy controls [19].
Nasr et al. also studied the andrological proﬁle of 24 men with RA
(mean age 31.3§ 7.3 years) and compared them to 18 healthy controls
(mean age 30.8 § 7.4 years). They found that RA patients have statisti-
cally signiﬁcant lower DHEA (71.13 § 22.71 vs 236.61 § 105.41 ug/dl,
p<0.001), total testosterone (1.5 § 0.6 vs 4.7 § 1.7 ng/ml, p<0.001)
and free testosterone levels (32.7 + 14.2 vs 188.0 + 70.5 pg/ml,
p<0.001) [20].
In one of the few prospective studies identiﬁed in this SR, a group
of 41 RA male patients (mean age 53 years) were followed from dis-
ease onset through 2 years by Tengstrand et al. Early in the disease
course, RA patients younger than 50 years had lower mean testoster-
one than controls (16.2 [standard deviation 3.5] vs 23.3 [standard
deviation 7.5] UI/l, p=<0.001). A reduction of disease activity (lower
DAS28 score) during the 2-year follow up correlated signiﬁcantly
with an increase in testosterone levels (rs=0.46, p = 0.006).[22]
Fertility
No studies were included.
Pregnancy and offspring outcomes
Using data from a nationwide Norwegian registry, Wallenius et al.
reported no increased risk of adverse pregnancy outcomes or pre-
eclampsia in partners of men with inﬂammatory joint disease,
regardless of whether the father had or had not been exposed to Dis-
ease-Modifying Anti-Rheumatic Drugs (DMARDs) [23]. In a similar
study, data from a Danish population-based cohort were presented
by Rom et al. where paternal RA was not found to be associated with
reduced fetal growth or preterm birth among 1086 children exposed
to paternal RA compared to non-exposed children [24].Systemic Lupus erythematosus
Sexual function
Sexual function in Systemic Lupus Erythematosus (SLE) was
reported in 4 studies from Latin America, using the following out-
come measures: IIEF in 1 article and interview in 3 articles. These
studies included data on 229 patients with a mean age of 31.5 years
and 175 healthy controls with a mean age of 28.8 years.
SD prevalence ranged from 12 to 68% in SLE patients compared to
0 to 22% in healthy controls. The association between disease activity
and SD was analyzed in 2 studies and no association was reported
[25,26]. In a multicenter study from Latin America that included 174
young SLE patients (mean age 36.1 § 1.0 years) a signiﬁcantly
increased prevalence of ED in men with SLE compared to controls
(68% vs 22%, p = 0.001) was reported. Among these patients the pres-
ence of persistent lymphopenia (1000 cells/mcl at three consecutive
times, p = 0.006) and the use of prednisone (9.3 § 1.2 vs 5.3 § 1.2 mg,
p = 0.026) were recognized as independent risk factors for ED (OR
2.79, CI95% [2.795.70], p = 0.001 and 2.15, CI95% [1.373.37],
p = 0.001, respectively). Interestingly, only 7% of patients had been
questioned about their sexual function in the previous 3 visits to the
rheumatologist while 82% of the patients considered it would be
appropriate to be asked about it [25].
Using a self-administrated questionnaire Silva et al. reported a
prevalence of ED of 20% in 25 SLE young patients (mean age 26 years)
compared to 0% in 25 healthy controls (mean age 27 years)
(p=<0.0001) [26]. In 2 similar studies that also included young SLE
patients (mean age 27 and 36 years, respectively), the prevalence of
SD was found to be signiﬁcantly higher in SLE patients compared to
age-matched controls (12% vs 0% and 30 vs 0%, respectively) [27,28].
Reproductive hormones
Higher levels of FSH and LH, an indication of hypogonadism, in
SLE patients compared to healthy control were a common ﬁnding in
5 studies included for this section. Unfortunately, the cause of hypo-
gonadism in these men was not established.
In a study that included 25 young SLE patients (mean age 27 years
[1545]) and 25 age-matched healthy controls, it was shown that
SLE patients had higher median FSH (5.8 [2.125] vs 3.3 [19.9] IU/L,
p = 0.002) and higher median LH (5.8, CI95% [1.415.6] vs 3.7, CI95%
[1.85.8] IU/L, p = 0.008) levels than controls. Low morning total tes-
tosterone levels were reported in 6 (24%) SLE patients compared to 0
controls [27]. Gonadal function was assessed by Soares et al. and they
found that SLE patients with severe sperm abnormalities (azoosper-
mia/oligospermia) had signiﬁcantly higher median FSH level than
patients with mild sperm abnormalities (10.9, CI95% [3.925] vs 3.3,
CI95% [117.9] IU/L, p = 0.0001) [29].
Testicular cell function was determined by measuring serum
inhibin B levels in a study that included 34 SLE patients (age 1545
years) and it was reported that 8 (23.5%) patients had low serum
inhibin B levels. This was associated with higher levels of FSH and LH
and with lower sperm concentration, sperm count and motile sperm
count [30]. In a small study that included 4 patients with juvenile-
onset SLE, only one patient with sperm abnormalities had high FSH
levels and a slight elevation of LH levels [31].
In a recent study by Tiseo et al. that included 28 young SLE
patients (mean age 33 years) the median level of LH (6.5, CI95%
[1.813] vs 3.95, CI95%[1.97.9] IU/L, p = 0.001) and total testoster-
one levels (500, CI95% [2621500] vs 389, CI95% [162729] ng/dl,
p = 0.002) were signiﬁcantly higher in SLE patients compared to 34
age-matched controls [32]. A potential limitation of this study was
the exclusion of azoospermic SLE patients.
Fertility
Fertility parameters were reported in 9 studies, mainly from Brazil
(n = 7). These studies included data on 263 SLE patients with a mean
Fig. 1. Flowchart of study selection.
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30.4 years. Sperm abnormalities, mainly lower median total sperm
count, were a common ﬁnding in SLE patients. Infertility and subfer-
tility as measured by the number of children per man, severe sperm
abnormalities and the DNA fragmentation index (DFI) was also aTable 1
Number of articles included per disease.
Disease Number of articles included Sexual fu
Rheumatoid arthritis 11 8
Systemic Lupus Erythematosus 10 4
Ankylosing Spondylitis 24 17
Systemic Sclerosis 7 7
Behc¸et Syndrome 9 5
Sarcoidosis 16 0
Antiphospholipid syndrome 4 2
Vasculitis 3 0
Auto-inﬂammatory syndromes 4 0relevant ﬁnding in 3 studies. Cyclophosphamide (CYC) was used in
more than half of patients but could not solely explain these ﬁndings.
Soares et al. reported a signiﬁcantly lower testicular volume in 35
SLE patients compared to controls (15 vs 20 ml, p = 0.003) and lower
median total sperm count (70 £ 106 vs 172 £ 106, p = 0.002). Innction Reproductive hormones Fertility Pregnancy outcome
3 0 2
5 8 0
2 7 0
0 1 0
0 4 1
1 15 0
0 3 0
2 0 1
2 1 1
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guidelines [29]. In contrast, Suehiro et al. reported no difference in
testicular volume among patients and controls [30].
Farhat et al. prospectively investigated the correlation of air pollu-
tants exposure concentrations and semen quality in SLE patients and
found that only CYC use and ozone had an association with sperm
quality abnormalities. Even in patients not exposed to CYC a detri-
mental effect of ozone exposure on semen quality of SLE patients was
observed [33].
Klinefelter syndrome (KS) may predispose men to develop SLE
and primary testicular failure. An increased prevalence of KS in men
with SLE was reported in a study that included 212 men with SLE
(235 per 10,000 male SLE patients vs 17 per 10,000 in live male
births). Interestingly, all SLE patients that were known to be infertile
had KS. The authors went further recommending that any male SLE
patient whose fertility is questionable should be evaluated for fea-
tures of KS [34].
Regarding juvenile-onset SLE, a small study that included 4
patients (mean age 19 years) also demonstrated semen quality
abnormalities in all of these patients; nonetheless, a medication
effect could be responsible for these ﬁndings [31].
The integrity of genetic material in the spermatozoon is of essen-
tial importance for successful fertilization. The sperm DNA Fragmen-
tation Index (DFI), a novel diagnostic tool used in infertility clinics,
measures sperm DNA damage. DFI levels above 25% are strongly
associated with infertility. DFI was signiﬁcantly higher in SLE patients
compared to controls (62, CI95% [31-97]% vs 25.5, CI95% [0-100]%,
p=<0.001) in a study were conventional sperm parameters were sim-
ilar in both groups. Interestingly, no correlations were found between
DFI with disease activity (SLEDAI-2 K and SLICC/ACR-DI) or medica-
tion use [32].
Information about the number of children per man diagnosed
with SLE was reported in 2 studies. In the study by Silva et al. the per-
centage of partners with gestations was statistically lower in SLE
patients compared with 25 age-matched healthy controls (20% vs
60%, p = 0.0086).[26] Soares et al. reported that 20% of SLE patients
fathered children after disease onset, compared with 80% controls
(p = 0.0001) [29].Pregnancy and offspring outcomes
No articles were included.Antiphospholipid syndrome
Only 2 studies and 2 case reports of antiphospholipid syndrome
(APS) patients were included.
In a small study that included 11 patients with APS (mean age
46.2 years), ED was observed more frequently in APS than in 22 age-
matched controls (45.5% vs 4.5%) and previous arterial thrombosis
was signiﬁcantly higher in patients with ED compared to those with-
out ED (100% vs 16.7%, p = 0.0152) [35].
ED was signiﬁcantly higher in 12 APS patients (mean age 37.5
years) than in 20 age-matched controls (25% vs 0%, p = 0.044). Median
sperm concentration, sperm motility, and normal sperm forms were
comparable in APS patients and controls (141.5, CI95% [33575] vs.
120.06, CI95% [34.5 329]x106/ml, p = 0.65; 61.29, CI95% [2580] vs.
65.42, CI95% [4382]%, p = 0.4; 21.12, CI95% [1042.5] vs. 23.95,
CI95% [10 45]%, p = 0.45, respectively), and none of them had oligo/
azoospermia. The median penis circumference was signiﬁcantly
lower in APS patients with ED vs those without ED (8.1, CI95% [610]
vs 10.2, CI95% [1011] cm, p = 0.007) [36]. Testicular thrombosis sec-
ondary to APS was described in case reports [37,38].Spondyloarthropathies
From the long list of diseases classiﬁed as spondyloarthropathies,
our SR search strategy only identiﬁed articles that reported SD in AS
(n = 15) and psoriatic arthritis (PsA) (n = 1).
Sexual function
A total of 15 studies were included in this section where many dif-
ferent questionnaires were used (IIEF used in 7 articles). In summary,
884 AS patients with a mean age of 37.9 years answered question-
naires or interviews for SD screening. Most of these studies are from
Turkey [8], followed by Korea with 2 studies and India, Morocco,
Tunes, China and Brazil with 1 study each. It was reported that SD
can be a problem for 3082.5% of male patients with AS (vs
12.543% in healthy controls), this was associated with disease activ-
ity, disease duration, depression, fatigue and limited joint mobility
[3954].
In a study that included 73 patients with AS, Rostom et al.,
reported that 70 (95.9%) patients had never been asked before by
doctors about sexual activity [40]. Interestingly, 3 studies from Tur-
key reported a lower or similar prevalence of SD in patients and
healthy controls [4244]. Speciﬁc ﬁndings per article can be found in
Table 2.
Reproductive hormones
Two studies performed an andrological evaluation in men with
SpA. Hypogonadism was associated with inﬂammation in SpA
patients in Italian patients [55] while in a Brazilian study the concen-
tration of LH, FSH and testosterone was comparable among AS
patients and healthy controls [56].
The Italian study included 10 young patients (mean age 28.7 § 8.6
years) diagnosed with AS or PsA (n = 5/5) and a statistically signiﬁ-
cant difference in plasma hormone levels between patients and 20
age-matched healthy controls was detected: in patients LH and FSH
values were higher (7.2, CI95% [4.57.9] and 5.7, CI95% [3.512.1]
UI/L vs. 3.6, CI95% [3.14.2] and 3.4, CI95% [2.64.1] UI/L, respec-
tively, both p=<0.01) and testosterone was lower (14.2, CI95%
[9.918.1] vs. 20.4, CI95% [18.1 22.5] nmol/L, p=<0.01). After 1 year
of treatment with TNF inhibitors normal hormone levels were
observed in this group [55].
Testicular Sertoli function was also evaluated in AS using inhibin
B. It is considered an important marker of gonadal function and sper-
matogenesis. Median inhibin B levels were lower in AS patients and
controls (68, CI95% [23265] vs 112.9, CI95% [47.8231.9] pg/ml,
p = 0.111). Other hormones, such as FSH and LH were similar in both
groups [56].
Fertility
Five studies analyzed the impact of AS on sperm quality and
reported inconsistent results. In total, data from 158 SpA patients,
mainly diagnosed with AS (mean age 32.9 years) and 231 healthy
controls (mean age 33.5 years) were included. This population was
more heterogeneous, 3 studies are from Europe, 1 from Latin America
and 1 from Asia. No differences in the semen quality between
patients and healthy controls were reported in 3 studies, but the
presence of varicocele was signiﬁcantly higher in patients compared
to controls in 2 studies and this was associated with semen quality
abnormalities. In 2 studies, sperm motility was signiﬁcantly reduced
in SpA patients. This was associated with disease activity and
improved after treatment with TNF inhibitors. In addition, an
increased rate of infertility was reported in one study.
Ramonda et al. detected a signiﬁcant reduction in the percentage
of progressive and non-progressive motile sperm in 10 AS patients
(mean age 28.7 years) compared to 20 age-matched controls. Impor-
tantly, a possible inﬂuence of disease activity on semen quality was
detected as these abnormalities improved after treatment with TNF
Table 2
Summary of sexual function results.
Study Number of cases/controls
(mean age in years)
Diagnostic/Screening tool used Main ﬁndings Study type and Quality
assessment (NOS)
Rheumatoid arthritis
Elst [14] Netherlands Cases: 32 (46.2 § 7)
Controls: 236 (NA)
Interview and sexual motivation
scale
Impotence was signiﬁcantly more prevalent in RA patients than in age-matched controls (62% vs
40%, p<0.05)
Patients with tender joint count <6 had stronger sexual motivation than those with >6.
No statistically signiﬁcant difference was found between disease activity and lower sexual interac-
tion.
27% of patients wanted advice for their sexual problems
Case-control
2
Blake [15] USA Cases: 32 (57.2)
Controls: 21 (55.1)
Interview and the Azrin Marital
Happiness Scale (AMHS).
Impotence prevalence was statistically signiﬁcant in RA patients compared to controls (62%  40%).
 Associated with older age, DM2, hypertension and methotrexate use.
Depression was not associated with impotence.
Case-control
5
El Miedany [16] Egypt Cases: 91 (51.4 + 9.4)
Controls: NA
IIEF SD reported by 53.8% of male patients with RA.
SD correlated with:
 Pain score, cardiovascular disease, age, disease activity, psychological status, fatigue score, num-
ber of intramuscular steroid injection, tender joint count.
No correlation with DMARDs or oral steroid therapy.
Cohort
2
Gaber [17] Egypt Cases: 29 (45.2 § 12.1)
Controls: 36 (43.2 § 9.7)
IIEF SD present in 48.3% of RA patients (33.3% in controls).
SD signiﬁcantly associated with:
 Longer morning stiffness duration.
 Higher DAS28 score.
Case-control
3
Van Berlo [18] Netherlands Cases: 76 (57.6 [SD 10.6])
Controls: 54 (54.9 [SD 9.4])
Questionnaire for screening sex-
ual dysfunctions (QSD)
Statistically signiﬁcant differences among RA patients and controls:
 Feel any desire for sexual contact with their partner (85% vs 96%)
Masturbate (52% vs 79%).
 Have sexual daydreams or fantasies (65% vs 89%).
Physical functioning, disease duration and activity correlated with various sexual problems.
41% of men had troubles with several joints during sexual activities.
Case-control
6
Gordon [19] Scotland Cases: 31 (55)
Controls: 95 (NA)
Interview 33% of RA patients admitted periods of impotence and 50% experienced decreased libido. Case-control
3
Nasr [20] Egypt Cases: 24 (31.3 § 7.3)
Controls: 18 (30.8 § 7.4)
IIEF 45.8% of patients with RA were diagnosed with ED compared to 11.1% of controls.
 20.8% of RA patients had moderate ED compared to 0% of controls.
No signiﬁcant correlation found between IIEF and disease activity.
Signiﬁcant correlation found between dehydroepiandrosterone (DHEA) levels, total and free tes-
tosterone levels and IIEF score.
Case-control
4
Keller [21] Taiwan Cases:6310 (NA)
Controls: 37,860 (NA)
ICD-9 diagnosis The OR for prior RA among cases with ED was 1.67 (95%, CI 1.36  2.05) that of controls after
adjusting for several factors.
Cohort
4
Systemic lupus erythematosus
Merayo-Chalico [25] Mexico Cases: 174 (36.1 § 1.0)
Controls: 105 (NA)
IIEF Prevalence of SD in SLE patients was 68% vs 22% in healthy controls (p = 0.001).
Signiﬁcant differences were reported among patients with SLE and SD and those without SD:
 Presence of persistent lymphopenia (1000cells/mcl at three consecutive times, p = 0.006).
 Higher prednisone dose (9.3 § 1.2 vs 5.3 § 1.2 mg, p = 0.026).
 SLICC damage score (1.25 § 0.14 vs 0.80 § 0.16 points, p = 0.042).
No difference regarding disease activity (SLEDAI score 4.89 § 0.54 vs 3.65 § 0.52, p = 0.16).
Only 7% of patients had been questioned about their sexual function.
 82% of patients considered it would be appropriate to be asked about their sexual function
Cross-sectional 4
Silva [26] Brazil Cases: 25 (26)
Controls: 25 (27)
Interview SD present in 20% of SLE patients compared to 0% in healthy controls (p = 0.0001).
The SLEDAI [0 (012) vs 0 (06), P = 0.295] and SLICC/ACR-DI [0 (01) vs 0 (03), P = 0.36]
medians were similar in SLE patients with SD/ED in comparison with those with normal function.
Case-control
3
Rabelo-Junior [28] Brazil Cases: 10 (36.9)
Controls: 20 (32.4)
Self-administered non speciﬁed
questionnaire
SD signiﬁcantly higher in SLE patients compared to controls (30% vs 0%, p = 0.029). Cross-sectional
5
Vecchi [27] Brazil Cases: 25 (27)
Controls: 25 (27)
Interview SD present in 12% of SLE patients vs 0% in controls, p = 0.0638.
None of the patients or controls had ED.
Frequency of sexual intercourse was similar among both groups.
Case-control
8
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Table 2 (Continued)
Study Number of cases/controls
(mean age in years)
Diagnostic/Screening tool used Main ﬁndings Study type and Quality
assessment (NOS)
Antiphospholipid syndrome
Lopes Gallinaro [35] Brazil Cases: 11 (46.2 § 9.4)
Controls: 22 (42.3 § 6.0)
IIEF SD was signiﬁcantly observed more frequently in APS than controls (45.5% vs 4.5%, p = 0.0096).
Moderate/severe ED was more common in APS than controls (36.4% vs 0%, p = 0.0081).
Erectile function and intercourse satisfaction were the areas with the most signiﬁcant differences
among APS patients and controls.
Arterial events were signiﬁcantly higher in APS patients with SD than those without SD (100% vs
16.7%, p = 0.0152).
Cross-sectional
4
Rabelo-Junior [36] Brazil Cases: 12 (37.5)
Controls: 20 (32.4)
Erectile dysfunction was signiﬁcantly higher in APS patients than in controls (25% vs 0%, p=0.044).
42% of APS patients with previous arterial thrombosis had SD compared with no patients with arte-
rial events (p = 0.204).
Cross-sectional
5
Spondyloarthropathies
Dhakad [39] India Cases: 100 (34.42 § 9.78)
Controls: 100 (36.39 § 8.07)
IIEF SD was more common in AS patients:
 Erectile function, orgasmic function, intercourse satisfaction and overall satisfaction were found
to be signiﬁcantly lower in the AS group as compared to controls .
ED in 42% of AS patients (vs 18% in controls, p = 0.0006)
 Associated with higher age, longer AS duration, anxiety, depression and higher BASFI.
Case-control
5
Rostom [40] Morroco Cases: 110 (38.9 § 12.5)
Controls: NA
Self-administered questionnaire 95.9% had never been asked about sexual activity by their doctors and 41% discussed the impact of
AS on sexual activity with their partners. From those sexually active:
 44% were unsatisﬁed.
 41% reported ED.
 38.4% had orgasmic problems.
What is the cause of your sexual problems?
 Fatigue (90%).
 Pain (69%).
 Depression (62.5%).
Cross-sectional
2
Sariyildiz [41] Turkey Cases: 70 (36.4 § 7.4)
Controls: 60 (35.2 § 7.7)
IIEF Patients with AS had signiﬁcantly lower scores in each of the 5 domains of the IIEF compared to
healthy controls (p=<0.05).
Negative correlation between BASFI scores and IIEF scores (p=<0.01).
 BASFI was independently associated with orgasmic function, sexual desire, intercourse satisfac-
tion and overall satisfaction.
BASDAI negatively correlated with erectile function, intercourse satisfaction and IEEF total scores
(p=<0.05).
 BASMI was independently associated with erectile function (p < 0.05)
Cross-sectional
4
Rezvani [42] Turkey Cases: 39 (38)
Controls: 27 (30)
IIEF Prevalence of ED was higher in healthy controls compared to patients with AS (51.9% vs 43.%,
respectively, p = 0.512).
Case-control
3
Tarhan, [43] Turkey Cases: 50 (38.5 § 10.3)
Controls: 50 (38.7 § 7.0)
Interview Similar prevalence of premature ejaculation in AS patients and healthy controls (32 and 30%,
p = 0.331).
Case-control
3
Ozkorumak [45] Turkey Cases: 43 (36.2 § 8.7)
Controls: 43 (36.5 § 6.5)
DSM-IV criteria (diagnosis con-
ﬁrmed by psychiatrists) and
Glombok-Rust Inventory of
Sexual Satisfaction (GRISS)
SD diagnosis established in 41.9% of patients vs 14.6% of controls (p = 0.08).
GRISS total score modestly correlated with depression and anxiety scores and with disease activity
(BASDAI).
GRISS scores signiﬁcantly higher in AS patients than controls.
Signiﬁcant differences in:
 Premature ejaculation
 Dissatisfaction
 Impotence
Cross-sectional
5
Bal [44] Turkey Cases: 37 (42.8 § 10.8)
Controls: 67 (43.6 § 5.9)
IIEF Prevalence of ED similar between patients and controls (35.1% vs 26.9%, p = 0.335).
The only statistically signiﬁcant difference was detected in sexual desire (lower in AS patients,
p = 0.014).
No correlation between IIEF scores, AS disease duration and activity parameters was reported.
Cross-sectional
4
Oh [46] Korea Cases: 22 (37.8)
Controls: NA
IIEF 63.6% of AS patients had ED.
 Decreased to 45.5% after 3 months of anti-TNF therapy.
There were signiﬁcant improvements in 4 IIEF-5 domains after 3 months of anti TNF therapy (all
except orgasmic function).
Cross-sectional
2
(continued on next page)
A
R
T
IC
L
E
IN
P
R
E
S
S
8
L.F.Perez-G
arcia
etal./Sem
inars
in
A
rthritis
and
Rheum
atism
00
(2020)
1
17
Table 2 (Continued)
Study Number of cases/controls
(mean age in years)
Diagnostic/Screening tool used Main ﬁndings Study type and Quality
assessment (NOS)
Cakar [47] Turkey Cases: 53 (32.8 § 12.1)
Controls: NA
Interview “According to you,
does AS affect you negatively
during sexual intercourse?”
50.94% of AS patients admitted as affected with regard to sexual intercourse.
Patients with lumbar column and hip involvement and those with higher depression scores were
more likely to report sexual intercourse dissatisfaction.
Cross-sectional
3
Dincer [48] Turkey Cases: 65 (32.98 § 11)
Controls: 45 (30.1 § 6.2)
Brief Male Sexual Function
Inventory (BMSFI)
Patients with AS had signiﬁcantly lower sexual drive, problem assessment, erection and overall sat-
isfaction scores compared with healthy controls.
20.5% of AS patients were signiﬁcantly more likely to report that they were not sexual satisﬁed vs
8.8% of healthy controls (p=<0.05).
SD associated with depression and limited joint mobility (BASMI)
Case-control
6
Pirildar [49] Turkey Cases: 65 (36 § 8.1)
Controls: 65 (37 § 5.2)
IIEF AS patients had signiﬁcantly lower erectile function, orgasmic function, intercourse and overall sat-
isfaction scores (p=<0.05).
12% with AS had mild or moderate ED (controls not reported).
ED was associated with morning stiffness (>4 h).
Case-control
4
Shen [51] China Cases: 78 (40)
Controls: NA
Modiﬁed Body Image
Questionnaire
56.3% of AS patients reported impaired sexual function (vs 29.8% in controls, p<0.001).
Disease activity, body image disturbance and physical impairments were linked with impaired sex-
ual functioning.
Cross-sectional
5
Younes [52] Tunisia Cases: 42 (36 § 8.1)
Controls: NA
Interview 44% AS patients reported sexual problems and 40% reported negative reactions of their spouses to
the disease.
BASMI >4 was associated with sexual problems.
Cross-sectional 5
Santana [53] Brazil Cases: 40 (45.8 § 11.4)
Controls: 40 (46 § 11.1)
IIEF IIEF total score was lower in AS patients than in controls (22 vs 29 points, P=<0.0001).
82.5% of AS patients had mild to severe ED compared to 12.5% of controls (p=<0.001).
Disease activity (BASDAI) was associated with sexual impairment (p=<0.001)
Cross-sectional
3
Gallinaro [54] Brazil Cases: 28 (43.9)
Controls: 28 (38.4)
Interview
Sexual activity questionnaire
61.9% of patients reported pain after sexual relationship, spine mobility was reduced in 95.2% of
these patients.
85.% of patients reported achieving sexual satisfaction.
Correlation with longer disease duration and higher disease activity scores (BASFI, BASDAI)
Cross-sectional
4
Systemic sclerosis
Hong [68] Canada & USA Cases: 48(52 § 1.7)
Controls: 55 (53 § 2.3)*
*Controls: RA patients
IIEF ED prevalence was signiﬁcantly higher in SSc patients than RA patients (81% vs 48%, p=<0.05).
For the majority of these patients, ED symptoms began after disease onset.
Raynaud’s phenomenon (RP) was associated with ED (Relative risk (RR)=4.0, p=<0.01).
Case-control
3
Ostojic [62] Serbia Cases: 5 (38.8)
Controls: NA
IIEF 3/5 patients reported that impotence occurred “very early” in their disease (average 4 months after
ﬁrst symptom).
Patients with ED had:
 Higher skin scores.
More lung ﬁbrosis on chest X-rays.
More restrictive lung disease.
1 patient developed Peyronie’s disease (ﬁbrosis of corporal body and penile skin).
Case series
8
Proietti [63] Italy Cases: 14 (41)
Controls: NA
IIEF
Duplex ultrasound (US)
Almost all patients were found to have moderate or severe degrees of vasculogenic SD.
Erectile function domain score were signiﬁcantly improved by once-daily tadalaﬁl (13.0 § 6.8 to
17.0 § 9.0, p < 0.05)
Cohort
2
Rosato [64] Italy Cases: 20 (49)
Controls: NA
IIEF
Videocapillaroscopy
Doppler US
All patients presented moderate to severe ED (100%).
Reduction of arterial ﬂow was present in all SSc patients.
Venocclusive dysfunction was evident in 55% patients.
A high degree of arteriolar damage was evident.
No association with videocapillaroscopy abnormalities.
Cross-sectional
6
Foocharoen [66] European
multicenter
Cases: 130 (52.3)
Controls: NA
IIEF 81% of SSc patients had variable degrees of ED.
 The largest group of all participants (38%) had severe ED.
 90.1% of patients reported that ED began after disease onset.
The presence of ED was associated with more severe organ involvement.
Cohort
5
Sanchez [67] France Cases: 13 (55.9)
Controls: NA
IIEF ED was found in 87.5% of SSc patients (mean IIEF-5 score 21 (mean [SD]: 16.0 [5.3]). Cross-sectional
6
Aversa [65] Italy Cases: 15 (47 § 12.5)
Controls: NA
IIEF
Doppler US
High incidence of ED (86%, mean IIEF score 13.3), positively correlated with age and disease duration.
All of the patients (irrespective of ED status) had a marked reduction of arterial ﬂowwith the pres-
ence of concomitant mild venoocclusive dysfunction in 66%.
Case-series
8
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patients (mean age 34.7 years [S.D. 9.2]) with high disease activity
(mean BASDAI 7.5 [S.D. 1.1] and mean CRP 2.9 mg/dl [95% CI 2.1,
3.6]). Interestingly, no statistically differences were noticed when
comparing samples from active patients and healthy controls (nor-
mospermia in 91% vs 71.4%, respectively [57]. No differences in sperm
quality between AS patients and healthy controls were reported in
other studies [56,58] (See Table 4).
In a small study from Villiger et al. semen quality of 26 SpA
patients with and without TNF inhibitors was compared. Sperm
abnormalities were more frequent in patients without TNF-inhibitors
(10/11) than in patients with TNF-inhibitors (11/15). Patients without
TNF-inhibitors had poorer sperm motility and vitality (p = 0.001). No
signiﬁcant correlation between disease activity (BASDAI/C-Reactive
protein) and sperm quality was reported [59].
The incidence of varicocele was signiﬁcantly higher in AS patients
than in healthy controls in two studies (40 vs 8%, p = 0.027 and 52 vs
20%, p = 0.009). This was also associated with sperm abnormalities
[58,60].
In a study by Uzunaslan et al., an increased rate of infertility in
men after a diagnosis of AS was reported (9.1% vs 2.9% in healthy con-
trols, p = 0.404) and AS patients had fewer children than healthy con-
trols (1.921 vs 2.466, p = 0.013).[61]
Pregnancy and offspring outcomes
No articles were included.
Systemic sclerosis
Sexual function
Seven studies that included 24 Systemic Sclerosis (SSc) patients
with a mean age of 47.2 years fulﬁlled the inclusion criteria (6 studies
from Europe and 1 from North America). Using the IIEF in 7 studies,
the prevalence of SD in men with SSc was very high, ranging from
60% to 100% (healthy controls were not included in these studies).
Damage to small blood vessels and ﬁbrosis are responsible for many
of the clinical manifestations of SSc. These factors are also important
in the pathogenesis of SD and the association between them and the
presence of SD in men with SSc has been studied by several groups.
In a small case series that included 5 young patients with SSc
(mean age 38.8 years) Ostojic et al. reported the impact of microvas-
culopathy and ﬁbrosis on the development of ED in men with SSc.
They found that ED was present in 60% of their patients. ED was a fre-
quent early clinical feature of SSc (average 4 months after presenting
the ﬁrst symptom). Although microvascular abnormalities were not
associated with ED, ﬁbrotic changes in the lungs were more frequently
reported in patients with ED. Interestingly, Peyronie’s disease, a
ﬁbrotic condition of the penis, developed in one SSc patient [62].
The extent of penile damage was investigated by Proietti et al. in 14
patients with diffuse or limited SSc by evaluating cavernous artery ﬂow.
They found that almost all patients had moderate or severe degrees of
vasculogenic-SD. Both, erectile function and vascular measures of cav-
ernous arteries improved after once-daily tadalaﬁl intake [63].
To investigate the association between vascular damage and ED in
SSc patients, Rosato et al. enrolled 20 SSc patients (mean age 49
years) and found that all had moderate to severe ED. Together with
ultrasound (US) ﬁndings, it was concluded that all of them had vascu-
logenic ED [64].
Aversa et al. included 15 patients with SSc in a study that used US
to describe the penile vasculature in SSc. A high prevalence of ED
(86%, mean IIEF score 13.3) was reported. All patients (irrespective of
ED status) had a marked reduction of arterial ﬂow with the presence
of concomitant mild venoocclusive dysfunction in 66% of them [65].
In the largest study known to date, a multicenter European cohort,
data of 130 SSc patients was collected and a prevalence of ED of 81%
(105/130) was reported. 40 (38%) patients had severe ED (IIEF-5 score
Table 3
Summary of reproductive hormones.
Study Number of cases/controls
(mean age in years)
Main ﬁndings Study type and Quality
assessment (NOS)
Rheumatoid arthritis
Gordon [19] Scotland Cases: 31 (55)
Controls: 95 (NA)
Patients with RA compared to AS patients and healthy controls showed
signiﬁcantly:
 Lower serum testosterone (p=<0.05).
 Signiﬁcantly greater serum LH (p=<0.05).
Serum FSH was signiﬁcantly higher in RA patients compared to controls but not in
AS patients.
Serum testosterone levels showed signiﬁcant negative correlations with ESR and
RF titers.
Case-control
3
Nasr [20] Egypt Cases: 24 (31.3 § 7.3)
Controls: 18 (30.8 § 7.4)
Patients and controls showed statistically signiﬁcant differences in:
 Lower DHEA (mean § SD: 71.13 § 22.71 vs 236.61 § 105.41 ug/dl, p = 0.000).
 Lower total and free testosterone (mean § SD: 1.5 § 0.69 vs 4.72 § 1.75 ng.ml,
p = 0.000).
Case-control
4
Tengstrand [22] Sweden Cases: 40 (53)
Controls: 131 (NA)
Compared to controls, patients younger than 50 years had:
 Lower testosterone concentrations (16.2 [3.5] vs 23.3 [7.5], [=<0.001).
 Lower SHBG concentrations (26 [7] vs 34 [12], p = 0.20).
 Lower NST concentrations (11.2 [2.5] vs 14.9 [4.5], p = 0.004)
Patients older than 50 years had on average signiﬁcantly lower LH levels than con-
trols (4.3 [3.3] vs 6.2 [2.1]. p = 0.001).
After 2 year follow-up:
Mean testosterone levels increased in the responder group but were unchanged in
the non-responders (17.7 [5.8] vs 13.9 [3.5], p = 0.25).
Lower disease activity did not affect LH, which remained low during the 2 years
follow-up period.
Case-control
6
Systemic lupus erythematosus
Vecchi [27] Brazil Cases: 25 (27)
Controls: 25 (27)
Median of FSH and LH were signiﬁcantly higher in SLE patients versus controls
(5.8 vs. 3.3 IU/l; 5.8 vs. 3.7 IU/l; respectively, p = 0.002).
The frequencies of elevated FSH and lower morning total testosterone levels were
signiﬁcantly higher in SLE patients compared with controls (28% vs. 0%; 24% vs.
0%; respectively, p = 0.009).
Case-control
8
Soares [29] Brazil Cases: 35 (28.9 § 8.8)
Controls: 35 (29.1 § 8.9)
FSH levels were higher in SLE patients with severe sperm abnormalities (3.3
[117.9] vs 10.9 [3.925] IU/l).
Elevated FSH levels were detected in 42.9% of patients who underwent IV CYC
therapy compared with 9.5% of those who did not.
Case-control
6
Suehiro [30] Brazil Cases: 34 (30)
Controls: NA
Eight SLE patients (23.5%) had low serum inhibin B levels (Group 1, median 11.05
pg/ml) and 26 (76.5%) had normal serum levels (Group 2, median 141.05 pg/ml).
Elevated FSH levels were detected in 100% of the patients of Group 1 compared
with none in the normal serum inhibin B Group.
Cross-sectional
3
Silva [31] Brazil Cases: 4 (19)
Controls: NA
Normal hormone levels in patients (FSH, LH, prolactin, testosterone). Case-series
7.5
Tiseo [32] Brazil Cases: 28 (33)
Controls: 34 (36.5)
Median of LH (6.5 vs 3.95 IU/L) and total testosterone levels (500 vs 389 ng/dl)
were signiﬁcantly higher in SLE patients compared to controls (p = 0.001).
Case-control
6
Spondyloarthropathies
Ramonda [55] Italy Cases: 10 (28.7 § 8.6)
Controls: 20 (27.4 § 4.2)
In AS patients LH and FSH values were higher (7.2 and 5.7 UI/L vs. 3.6 and 3.4 UI/L)
and testosterone was lower (14.2 vs. 20.4 nmol/L) (p = 0.01).
Case-control
4
Almeida [56] Brazil Cases: 20 (33)
Controls: 24 (28.5)
The median inhibin B levels were comparable in AS patients and controls (68 vs
112.9 pg/mL, p = 0.111).
The median of FSH levels (3.45 vs. 3.65 IU/L) and the other hormones were also
similar in both groups.
Cross-sectional
4
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prevalence of 87.5% and 81%, respectively [67,68].Fertility
The number of children per man can be considered as a good
proxy of fertility. Hong et al. compared this parameter in 48 patients
with SSc and 55 patients with RA and they found that patients with
SSc had signiﬁcantly fewer biological children than those with RA
[2.0 § 0.2 (0.4) vs 2.7 § 0.2 (0.5), respectively, p=<0.01]. Among
patients with SSc, and to a lesser extent RA, the presence of Ray-
naud’s phenomenon (RP) was signiﬁcantly associated with this ﬁnd-
ing (80% of patients with RP had ED vs 50% of patients without RP,
p=<0.01) [68].Reproductive hormones and pregnancy and offspring outcomes
No articles were included.Behc¸et syndrome
Sexual function
Sexual function in Behc¸et’s syndrome (BS) was reported in 5 stud-
ies from Turkey, using the following outcome measures: IIEF in 2
articles, interview in 2 articles and the Arizona Sexual Experience
Scale (ASEX) in 1 study. These studies included data on 164 patients
with a mean age of 37.2 years and 128 healthy controls with a mean
age of 36.1 years. In this group, the prevalence of SD ranged from 63
to 80% in BS and 32% in healthy controls.
In a small study of 19 male patients (mean age 39.1 years) diag-
nosed with Neuro-Behc¸et, ED was reported in 12 (63%) patients.
Mixed vasculogenic impotence was responsible for 63% of ED cases
[69]. Inspired by these ﬁndings, Aksu et al. reported 2 cases of ED in
patients with BS, they determined that the cause of ED was severe
venous leak possibly secondary to disease-related thrombosis [70].
In the ﬁrst study that used standardized methods (IIEF) to screen
for SD in 42 BS patients (mean age 33.7 years), Hiz et al. found that the
total IIEF score was signiﬁcantly lower in BS patients compared to 42
Table 4
Summary of fertility outcomes.
Study Number of cases/controls
(mean age in years)
Main ﬁndings Study type and Quality
assessment (NOS)
Systemic lupus erythematosus
Silva [26] Brazil Cases: 25 (26)
Controls: 25 (27)
Percentage of partner with gestation was statistically lower in SLE patients compared
to controls:
 20% vs 60% (p = 0.0086)
Regarding gonadal function:
 60% of SLE patients vs 0% if controls presented sperm quality abnormalities
(p = 0.001).
 Reduction of testicular volume correlated to semen abnormalities severity (sugges-
tion of severe lesion of the seminiferous tubules).
Case-control
3
Rabelo-Junior [28] Brazil Cases: 10 (36.9)
Controls: 20 (32.4)
Median right testicular volume by US was signiﬁcantly lower in SLE-APS patients
(10.38 (3.916.7) vs. 13.4 (8.520.6) mL, p = 0.03).
Median values of sperm concentration and spermmotility were signiﬁcantly lower in
SLE patients:
 Sperm concentration (41.1 [0145] vs 120 [34.5329] x 106/ml, p = 0.003).
 Sperm motility (47.2 [087.5] vs 65.42% [4382], p = 0.047).
Median penis circumference was signiﬁcantly reduced in SLE-APS patients with ED
compared to patients without ED (8.17 [88.5] vs. 9.14 [710.5] cm, p = 0.0397).
Cross-sectional
5
Farhat [33] Brazil Cases: 26 (29.8)
Controls: NA
An increase of 23.5 ug/m3 of ozone averaged over the 090 day period before collec-
tion of sample was associated with a decrease of 30.6 million spermatozoa/ml (95%
CI, 2.059.3; p = 0.040).
No effects were observed with other pollutants.
Cross-sectional
3
Vecchi [27] Brazil Cases: 25 (27)
Controls: 25 (27)
The median testicular volume by right and left Prader was signiﬁcantly lower in SLE
compared with controls (15 vs. 20 ml and 15 vs. 20 ml; respectively), p = 0.006.
Median penis length and circumference were signiﬁcantly lower in SLE compared with
controls (8 vs. 10 cm, p = 0.0001).
The frequencies of oligo/azoopermia (44 vs. 0%, p = 0.0002) and asthenozoospermia
(36 vs 0%, p = 0.0016) in SLE patients were higher than controls.
The median of sperm concentration, total sperm count, total motile sperm count,
spermmotility and normal sperm by WHO guidelines were uniformly and signiﬁ-
cantly lower in SLE patients versus controls.
Case-control
8
Soares [29] Brazil Cases: 35 (28.9 § 8.8)
Controls: 35 (29.1 § 8.9)
The median of the testicular volume in both testes according to Prader orchidometry
were signiﬁcantly lower in SLE patients than in controls (15 ml vs 20 ml at the right
testicle [p = 0.003] and 15 ml vs 20 ml at the left testicle [p = 0.004]).
All 35 male SLE patients (100%) had semen abnormalities according to WHO guide-
lines:
 SLE patients had a lower median total sperm count (70 £ 106 vs 172 £ 106, p = 0.002)
and a lower median total motile sperm count (32 £ 106 vs 119 £ 106, p = 0.004)
compared with controls.
Seven SLE patients (20%) fathered children after disease onset, compared with 28 con-
trols (80%), p = 0.0001.
No signiﬁcant difference regarding the presence of varicocele among both groups.
Case-control
6
Suehiro [30] Brazil Cases: 34 (30)
Controls: NA
No signiﬁcant difference in testicular volume in SLE patients with low or normal
inhibin B levels.
Patients with low inhibin B levels had lower median sperm concentration (2 vs 56.5
106/ml, p = 0.024), total sperm count (6 vs 133 106/ml, p = 0.023) and total motile
sperm count (3 vs 69.5 106/ml, p = 0.025) compared with patients with normal
inhibin B levels.
Inhibin B levels were positively correlated with sperm concentration and total motile
sperm count.
No signiﬁcant difference regarding the presence of varicocele among both groups.
Cross-sectional
3
Scoﬁeld [34] USA Cases: 76 (NA)
Controls: NA
Klinefelter’s syndrome (KS) prevalence of 264 per 10,000 men with SLE (>15 times
higher than the general population)
“Are you infertile?”
 All men subsequently found to have KS answered the question with a response other
than “no”.
 This question was 100% sensitive and 33% speciﬁc for identiﬁcation of KS in men with
SLE.
Cohort
4
Silva [31] Brazil Cases: 4 (19)
Controls: NA
Normal testicular volume in 100%.
Sperm quality abnormalities in 100%.
Case-series
7.5
Tiseo [32] Brazil Cases: 28 (33)
Controls: 34 (36.5)
The sperm DNA fragmentation index (DFI) was signiﬁcantly higher in SLE patients
compared to controls (62 [3197] vs 25.5 [0100]%, p=<0.001) in a study were con-
ventional sperm parameters were similar in both groups.
No correlations were evidenced between DFI with multiple variables: age, BMI, disease
duration, disease activity, cumulative doses of prednisone, cyclophosphamide,
methotrexate, azathioprine or mycophenolate mofetil.
Case-control
6
Antiphospholipid syndrome
Rabelo-Junior [36] Brazil Cases: 12 (37.5)
Controls: 20 (32.4)
Sperm quality was comparable in APS patients and controls:
 Sperm concentration: 141.5 [33575] vs. 120.06 [34.5 329] 106/ml, p = 0.65.
 Sperm motility: 61.29 [2580] vs. 65.42 [4382]%, p = 0.4.
 Normal spermmorphology: 21.12 [1042.5] vs. 23.95 [10 45]%, p = 0.45.
Cross-sectional
5
Rabelo-Junior [28] Brazil Cases: 10 (36.9)
Controls: 20 (32.4)
Median values of sperm concentration (41.1 vs. 120.06 £ 106/mL, p = 0.003) and sperm
motility (47.25 vs. 65.42%, p = 0.47) were signiﬁcantly lower in SLE-APS patients
compared to that in controls.
Cross-sectional
5
(continued)
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Table 4 (Continued)
Study Number of cases/controls
(mean age in years)
Main ﬁndings Study type and Quality
assessment (NOS)
The frequency of oligo/azoospermia was signiﬁcantly higher in SLE-APS patients
(40 vs. 0%, p = 0.007).
Spondyloarthropathies
Ramonda [55] Italy Cases: 10 (28.7 § 8.6)
Controls: 20 (27.4 § 4.2)
Semen analysis highlighted a signiﬁcant reduction in the percentage of progressive and
non-progressive motile sperm in patients compared with control subjects (p=<0.05).
Two inverse Spearman correlations were detected:
 CRP and percentage of sperm with normal morphology (P = 0.026; r=0.0728).
 DAS-28 and overall motility (p = 0.048; r= 0.949).
The other sperm parameters and the percentage of sperm aneuploidies in the SpA
patients did not show signiﬁcant differences.
Case-control
4
Nukumizu [58] Brazil Cases: 20 (33)
Controls: 24 (28.5)
AS patients and controls had normal external genitalia.
Sperm analysis was comparable in both groups.
Varicocele was found in 40% of AS patients compared to 8% of healthy controls and this
ﬁnding was associated with sperm abnormalities (p = 0.175).
Cross-sectional
4
Micu [57] Norway Cases: 23 (34.7)
Controls: 42 (34.8)
Sperm quality in patients with active AS was comparable to sperm quality in healthy
controls.
Case-control
4
Villiger [59] Switzerland Cases: 26 (30)
Controls: 102 (35)
Impaired sperm quality was especially found in AS patients without TNF-inhibitors and
active disease:
Sperm abnormalities were found in 10/11 patients without TNF-inhibitor therapy.
 Sperm of these 11 patients had signiﬁcantly poorer motility (p = 0.001) and vitality
(p = 0.001) compared to 15 patients tested during longstanding TNF-inhibitor
therapy.
Cross-sectional
4
Uzunaslan [61] Turkey Cases: 79 (38.3)
Controls: 43 (42)
Higher infertility rate after diagnosis in AS patients was reported (9.1%) but this was
not signiﬁcant compared to healthy controls (2.9%), p = 0.502.
AS patients had signiﬁcantly fewer children when compared with other groups
(p = 0.013):
 AS: 1.9
 BS: 2.3
 Familial Mediterranean Fever (FMF): 2.4
 Healthy controls: 2.4
Case- control
3
Systemic sclerosis
Hong [68] Canada & USA Cases: 48(52 § 1.7)
Controls: 55 (53 § 2.3)*
*Controls: RA patients
Patients with SSc had signiﬁcantly y lower number of biological children than patients
with RA (2.0 § 0.2 vs 2.7 § 0.2, p=<0.01).
Men with RP fewer children than men without RP (2.0 § 0.2 vs 2.6 § 0.2, p=<0.02).
Case-control
3
Bechet’s syndrome
Cetinel[74] Turkey Cases: 104(40)
Controls: 31 (29)
The frequency of epididymitis was signiﬁcantly higher in patients with BS than con-
trols (19.2 vs 0%, p = 0.001).
The frequency of infertility was higher in patients with BS than controls (9.6 vs 2.3%,
p=NA).
Case-control
5
Uzunaslan[61] Turkey Cases: 162 (39)
Controls: 43 (42)
Higher infertility rate after diagnosis in AS patients was reported (BS with major organ
involvement 7.95% and BS without major organ involvement 10.2%) but this was not
signiﬁcant compared to healthy controls (2.9%, p = 0.502)
 17.7 of male patients with BD was considered to have compromised fertility and
among them the most common etiology was varicocele.
The average number of children (2.3), miscarriages (0.4) and of children born with
congenital abnormalities (4.4) was similar to controls.
Case-control
4
Auger [76] France Cases: 68 (28)
Controls: 1448 (NA)
66.7% of patients with BS were considered normozoospermic.
Differences in the sperm concentration, count, motility and morphology were signiﬁ-
cant when comparing data to healthy controls.
Case-control
5
Table 5
Summary of pregnancy and offspring outcomes.
Study Patients/controls Findings Quality assessment
Rheumatoid arthritis
Rom [24] Denmark NA Among 1086 born children exposed to paternal RA:
 No statistically signiﬁcant associations were found with indicators of fetal growth, preterm
birth compared to the general population.
Cohort
8
Wallenius [23] Norway NA Among 2777 births from 1796 men with RA:
 Relative risks from serious malformation were not different between DMARD exposed and
non-exposed group.
 Birth weight was not different between groups.
Cohort
6
Bechet syndrome
Uzunaslan [61] Turkey Cases: 162 (39)
Controls: 43 (42)
The number of infants with congenital anomalies was not increased among patients with BS
when compared with other groups.
Case-control
4
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[standard deviation 0.750] p=<0.001). Scores of 26 or higher were con-
sidered as normal sexual function. Lower IIEF scores were associated
with higher depression scores. No association between ED and medi-
cation use or the presence of oral and genital ulcers was found [71].
The association between ED and depression in patients with BS
was further investigated by Gul et al. in a study of 24 BS male patients
(mean age 35.8 years). They reported that SD was signiﬁcantly more
prevalent in BS than in controls (80 vs 32%, p = 0.001). This was asso-
ciated with higher depression scores. Male patients with BS were
found to have more problems in the following areas: impotence, pre-
mature ejaculation and sexual satisfaction [72]. Similar ﬁndings were
reported by Batmaz et al. in a group of 72 sexually active male BS
patients (mean age 36.5 years) [73].
Fertility
Cetinel et al. sent questionnaires to 104 male patients with BS
(mean age 31 years) to screen for urologic manifestations and found
a signiﬁcantly high frequency of epididymitis in patients with BS
compared to controls (19.2 vs 0%, p = 0.001). They also found a higher
incidence of infertility and varicocelectomy in BS patients, but the
difference was not statistically signiﬁcant compared to healthy con-
trols [74].
The incidence of varicocele was also increased in BS in a study that
included 47 patients with BS (mean age 23.4 § 3.2 years) and 31 age-
matched healthy controls. Scrotal pain or a palpable mass was
detected by physical examination in 24 (51.1%) BS patients and in 5
(16%) healthy controls (p = 0.002). No sperm analysis was performed
in these patients [75].
A large study that included 162 male patients with BS, compared
fertility rates among them and patients with other rheumatic diseases
(AS, Familiar Mediterranean Fever (FMF)) and healthy controls). Inter-
estingly, a trend for an increased rate of infertility (deﬁned as the
inability to conceive after 1 year of unprotected intercourse) after diag-
nosis was found in all the groups with rheumatic diseases (BS: 9%,
FMF: 7.5% and AS 9.1%) but this was not signiﬁcant compared to the
rate seen in healthy controls (2.9%) (p = 0.404). With the exemption of
AS, the average number of children was similar among groups [61].
In the only identiﬁed study that investigated semen quality in BS
patients, Auger et al. using sperm banking data compared the sperm
characteristics of BS patients and healthy fertile men. Moderate alter-
ations in semen quality were observed. Of particular interest, the
authors reported that sperm alterations were present even before
treatment and this might be related to disease-related factors [76].
Reproductive hormones
No articles were included.
Pregnancy and offspring outcomes
The average number of miscarriages and the percentage of infants
born with congenital anomalies were not increased in children
fathered by patients with major organ BS when compared with
healthy controls (0.429 vs 0.398 and 4.49 vs 4.85%, respectively) [61].
Other rheumatic diseases
Sarcoidosis
In a study that included 30 patients diagnosed with sarcoidosis
(mean age 43.6 years), Spruit et al. found that sarcoidosis patients
were more likely to have lower median free testosterone concentra-
tions than 26 age-matched healthy controls [7.32 (5.488.72) vs 9.25
(7.549.87) ng/dl, p = 0.0062] [77].
Azoospermia, teratozoospermia and oligospermia were frequent
ﬁndings in case reports of patients with sarcoidosis [7886]. Treat-
ment with corticosteroids improved semen quality in some cases[79,80,86,87]. Granulomas were also reported in testicles and epidid-
ymis of patients with sarcoidosis [8892].
Vasculitis
Hypogonadism was reported in 10 out of 19 (52.6%) male patients
diagnosed with Granulomatosis with Polyangiitis (GPA) (mean age
58.4 years) compared to 0 out of 38 age-matched controls
(p=<0.001). No correlation with clinical factors or current/past medi-
cation use was found. Authors concluded that a subclinical involve-
ment of the testes in GPA patients was possible [93].
Androgen deﬁciency and its association with fatigue were ana-
lyzed in a study that included 70 male patients with ANCA-associated
vasculitis (mean age 59 years). A high prevalence of androgen deﬁ-
ciency among these patients was reported (47%) and testosterone
levels were associated with physical functioning and fatigue [94].
Pregnancy outcomes among partners of male patients with vascu-
litis were analyzed by Clowse et al. Data from 107 patients were
reported, 54 men reported conceiving 157 pregnancies. Pregnancy
loss rate was not signiﬁcantly higher among pregnancies conceived
following a diagnosis of vasculitis (n = 139) compared to those prior
to diagnosis (n = 18) (41.2% vs 23%; relative risk 2.34 [CI95% 0.71 
7.70], p = 0.16) [95].
Autoinﬂammatory syndromes
Azoospermia due to testicular amyloidosis in a patient with FMF,
conﬁrmed with a testicular biopsy, was reported [96]. Fever was
shown to drastically reduce sperm output and this was accompanied
by an increase in the percentage of abnormal spermatozoa in a study
conducted by French et al.[97]
The rate of abortions was comparable in 222 pregnancies among 60
partners of male patients diagnosed with FMF (7%) and 788 pregnan-
cies among 230 healthy womenmarried to healthy men (16%) [98].
A small retrospective study from France reviewed the medical
records of all male patients diagnosed with Muckle-Wells syndrome
(MWS) and NLRP3 mutations founding that 6 out of 9 patients were
unable to conceive a pregnancy despite regular sexual activity during
at least 2 years and that sperm quality was abnormal in 88% of the
samples obtained. Multiple mechanisms were discussed as possible
causes for this association, such as recurrent fever episodes, excessive
amounts of IL-1B and IL-18 [99].
Autoimmune diseases in general
Retrospective cohort studies from the United States have reported
an increased risk of developing any rheumatic disease in patients
diagnosed with hypogonadism and infertility. Among 123,460 males
diagnosed with hypogonadism (mean age 46.5 years) and 370,380
age-matched males not diagnosed with hypogonadism multivariable
analysis showed that untreated hypogonadism was associated with
an increased risk of developing any rheumatic autoimmune diseases
(3.2 versus 2.2%; HR = 1.33, 95% CI = 1.41, 1.52) [100]. Using the same
database, Brubaker et al. reported a higher risk of developing RA and
general immune disorders, like SLE, (HR 1.56, 95% CI 1.192.05 and
HR 3.11, CI95% 2.004.86, respectively) among 33,077 infertile men
(mean age 33 years) compared to 77,693 age-matched vasectomized
men [101].
Discussion
Summary of evidence
Sexual function
Our study found that male patients with rheumatic diseases have
a high prevalence of SD; this was statistically signiﬁcant in many
studies when comparing patients with rheumatic diseases to age-
matched healthy controls. In addition, SD seems to occur at a younger
age in patients with rheumatic diseases. For comparison, in a
ARTICLE IN PRESS
L.F. Perez-Garcia et al. / Seminars in Arthritis and Rheumatism 00 (2020) 117 15multicenter study that included data from 27,839 adult men (aged
2075 years), the overall self-reported prevalence of SD was 16% and
it ranged from 8% in men aged 2029 years to 37% in men aged
7075 years [102].
Recently, the EULAR published recommendations on screening for
and preventing selected comorbidities in chronic inﬂammatory rheu-
matic diseases [103]. As it is the case for these comorbidities (i.e. car-
diovascular disease, infections and depression), SD can represent an
important burden to male patients and contribute to a lower quality
of life. Most of these patients remain undiagnosed and uninformed
about SD. We encourage rheumatologists to talk about sexual health
with their patients. The use of widely available screening tools and
early referrals to specialists should be considered in men with rheu-
matic diseases and SD, especially those trying to conceive. For clinical
practice and future research projects in this topic, we recommend
the use of validated screening tools (I.E. IIEF for sexual dysfunction).
Rheumatic diseases can affect several organs via factors like sys-
temic inﬂammation in RA and SLE and ﬁbrosis in SSc. These factors
have been shown to be associated with the increased prevalence of
SD in men with rheumatic diseases. A link between RA-induced
inﬂammation and cardiovascular disease is already known and has
been widely studied. Based on our SR ﬁndings, it is plausible that a
similar link between RA-induced inﬂammation and the development
of SD exists and that it could be an early sign of endothelial dysfunc-
tion. In addition to the classical factors associated with SD such as
older age, depression and anxiety, this link could also play an impor-
tant role in the pathogenesis of SD in men with rheumatic diseases
In conclusion, SD is a common problem in male patients with
rheumatic diseases. This association might result from the fact that
several key factors contribute to the etiopathogenesis of rheumatic
diseases and SD.
Reproductive hormones
A clear effect of rheumatic diseases on the pituitary-testicular axis
exists. Hypogonadism and testicular dysfunction was a common ﬁnd-
ing, especially in patients with RA and SLE and this was associated
with disease activity. Especially in patients with SLE, differentiating
between primary (Klinefelter Syndrome, drug toxicity) and second-
ary hypogonadism (inﬂammation) should be considered in future
research projects and in the clinic.
Interestingly, when comparing the androgenic status of men with
RA and AS, a rheumatic disease that is more prevalent in men than
women, it was found that only RA had a detrimental effect on testicu-
lar function. It is possible that based on different inﬂammatory phe-
notypes, disease activity in RA and SLE can result in testicular
damage via different mechanisms.
Fertility
Infertility affects 1015% of men in their prime reproductive age
and the cornerstone of laboratory evaluation of infertile men is a con-
ventional semen analysis [104]. Semen quality in men with rheu-
matic diseases can be impaired in patients with SLE, SpA, sarcoidosis,
BD and MWS. Sperm count and motility were the most common
semen quality parameters affected. Systemic inﬂammation can cause
impaired spermatogenesis by mechanisms that have not been
described yet.
Varicocele, one of the most common ‘reversible’ causes of infertil-
ity in the general population, can be present in more than half of men
with AS and to a lesser extent in BS. Rheumatologists should be
aware of this association and actively screen it in every AS/BS patient
with a wish to conceive. We also encourage researchers to take this
association into account when studying semen quality of male
patients with AS (and other rheumatic diseases), since we believe
that some of the ﬁndings regarding impaired semen quality could be
associated with non-identiﬁed varicocele and not to the disease itself
or as a side effect of therapy.Unexplained subfertility is a common problem in women with RA
[105] but fertility status in men with rheumatic diseases has not been
extensively studied. Men with AS, SLE and SSc had a lower number of
children than controls in small studies, nevertheless, since many fac-
tors that might contribute to these ﬁndings such as voluntary child-
lessness (related or unrelated to the diagnosis of a rheumatic disease)
were not reported, larger epidemiological studies that take these fac-
tors into account are needed to verify this association.
Since conventional semen analysis can be normal in infertile
patients, DFI might be a better marker for infertility in men with SLE
and other rheumatic diseases. More studies are needed to make rec-
ommendations on the use of DFI in this population.
Pregnancy and offspring outcomes
The information regarding the inﬂuence of paternal RA and vascu-
litis on pregnancy outcomes is based on a few studies. We found no
evidence pointing towards a negative effect of paternal RA and vascu-
litis on pregnancy outcomes. Unfortunately, there is no information
about pregnancy outcomes in partners of male patients with other
rheumatic diseases and over the impact of paternal disease on off-
spring’s outcomes.
Conclusion
“A systemic disease is one that affects a number of organs and tissues,
or affects the body as awhole” [106]. The collaboration betweenmultiple
organs is needed to achieve full male sexual health and it is now evident
that many of these organs can suffer detrimental effects secondary to
rheumatic diseases. Rheumatic diseases and male sexual health should
not be considered anymore as being unrelated conditions.
Unfortunately, several limitations should be addressed; most of
the studies included small numbers of patients and controls. In addi-
tion, studies about sexual function and fertility in men with rheu-
matic diseases suffer from inconsistent methodological quality,
deﬁnitions of sexual dysfunction varied in several studies, a wide
variety of screening questionnaires and/or diagnostic tools were
used, relevant comorbidities that can also have a direct effect on sex-
ual function such as depression were not reported in all studies and
results might only apply to the speciﬁc populations studied.
More and better research is needed to fully understand the effect
of rheumatic diseases in male sexual health. Epidemiological, clinical
and basic science studies are needed and should be done in such a
way that results can be comparable in different populations. For this
reason, for future research we strongly advice on the use of standard-
ized methods and deﬁnitions. Collaboration between rheumatolo-
gists, andrologists and other experts on this topic is encouraged.
We also encourage rheumatologists and other clinicians taking
care of men with rheumatic diseases to consider male sexual health
in their clinical practice. Timely detection and treatment of SD and
fertility problems can have a big impact on the quality of life of
patients and avoid the use of expensive medical care. To achieve this,
rheumatologists and patients must have the opportunity and the nec-
essary tools to discuss this topic.
We conclude that male sexual and reproductive health is affected
by rheumatic diseases, the degree and extent of this is still unknown
and varies per disease. More research is needed and rheumatologists
should address this topic with their patients.
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